<DOC>
	<DOCNO>NCT01478581</DOCNO>
	<brief_summary>The primary objective study determine efficacy PCI-32765 , single agent combination dexamethasone , subject relapse relapsed refractory Multiple Myeloma ( MM )</brief_summary>
	<brief_title>Study Bruton 's Tyrosine Kinase Inhibitor Subjects With Relapsed Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>Bruton 's tyrosine kinase ( Btk ) enzyme present hematopoietic cell T cell necessary downstream signal transduction various hematopoietic receptor include B cell receptor well Fc , chemokine , adhesion receptor , crucial B cell development osteoclastogenesis . Although down-regulated normal plasma cell , Btk highly express malignant cell many myeloma patient cell line . PCI 32765 potent specific inhibitor Btk currently Phase 2 clinical trial . The current study design intend determine effect PCI-32765 subject MM .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Diagnosis symptomatic MM measurable disease , define least one following : 1 . Serum monoclonal protein ( Mprotein ) ≥0.5 g/dL determine serum protein electrophoresis ( SPEP ) 2 . Urine Mprotein ≥200 mg/24 hrs 3 . Serum free light chain ( FLC ) assay : involve FLC level ≥10 mg/dL ( ≥100 mg/L ) provide serum FLC ratio abnormal Relapsed relapsed refractory MM receive least 2 5 previous line therapy , 1 must immunomodulator . Refractory myeloma ( recent treatment ) define disease nonresponsive treatment progressive disease within 60 day completion precede treatment . Nonresponsive disease define either failure achieve minimal response development progressive disease therapy . Men woman ≥18 year age . ECOG performance status ≤ 1 . Subject must primary refractory disease define disease nonresponsive subject never achieve minor response ( MR ) good therapy . Polyneuropathy , organomegaly , endocrinopathy , Mprotein , skin change ( POEMS ) syndrome , osteosclerotic myeloma , CrowFukase syndrome . Plasma cell leukemia . Primary amyloidosis . Certain exclusion prior therapy . ANC &lt; 0.75 x 10^9/L independent growth factor support . Platelets &lt; 50 x 10^9/L ) independent transfusion support . AST ALT ≥3.0 x upper limit normal ( ULN ) . Total bilirubin &gt; 2.5 x ULN , unless due Gilbert 's syndrome . Creatinine &gt; 2.5 mg/dL . Unable swallow capsule disease significantly affect gastrointestinal function . Requires anticoagulation warfarin vitamin K antagonist . Requires treatment strong CYP3A4/5 inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>PCI-32765</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed Refractory Multiple Myeloma</keyword>
	<keyword>Bruton 's Tyrosine Kinase</keyword>
</DOC>